Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.

Simple item page
dc.contributor.authorIslam, M Nen_US
dc.contributor.authorAlam, M Nen_US
dc.contributor.authorHaq, S Aen_US
dc.contributor.authorMoyenuzzaman, Men_US
dc.contributor.authorPatwary, M Ien_US
dc.contributor.authorRahman, M Hen_US
dc.date.accessioned2000-04-24en_US
dc.date.accessioned2009-05-27T03:47:27Z
dc.date.available2000-04-24en_US
dc.date.available2009-05-27T03:47:27Z
dc.date.issued2000-04-24en_US
dc.descriptionBangladesh Medical Research Council Bulletin.en_US
dc.description.abstractEarly intervention with slow acting anti-rheumatic drugs (SAARDs) has led to improvement in substantial proportion of rheumatoid arthritis (RA) patients. The present open, controlled study was designed to assess whether a combination of SAARDs offer any added benefit. Fifty-four adult RA patients were randomly allocated to methotrexate (MTX) (n = 27) and MTX plus sulphasalazine (SSZ) (n = 27) groups. The subjects were followed-up fortnightly for four weeks then monthly for six months. The disease activity was assessed with the help of 10 clinical and four laboratory indices. The improvement was graded as: minor, mild decreases in indices, non-steroidal anti-inflammatory drugs (NSAIDs) continued, physician's global assessment (PGA) decreased by one; marked, acceptable decreases in indices, NSAIDs being taken sparingly, PGA decreased by at least 2, and complete, all indices normalised and patients discontinued NSAIDs completely. The improvement was considered clinically important when marked or complete improvement occurred. Adverse drug reactions resulted in withdrawal of 4 subjects from the MTX + SSZ group and 1 from the control groups. Four and three subjects in the combined and MTX groups respectively were lost to follow-up. Subjects in both groups showed significant decline in all indices except hemoglobin and neutrophil count. The differences between the two groups in the pre-treatment and post-treatment values were insignificant. Complete, marked, minor and no improvement occurred in 4 (21%), 12 (63%), 3 (16%) & 0 in the MTX and in 11 (48%), 7 (30%), 4 (17%) & 1 (4%) in MTX + SSZ groups respectively. The differences in the rates of complete and clinically important improvement between the two groups were insignificant (P 0.1398 and 0.7092). The incidence of side effects was insignificantly higher in the MTX + SSZ group. Most of them were mild and transient. The combination of SAARDs offered little added advantage in RA. However, the higher rate of complete improvement in the combination group justifies trials including larger samples.en_US
dc.description.affiliationDept. of Medicine, BSMMU, Dhaka.en_US
dc.identifier.citationIslam MN, Alam MN, Haq SA, Moyenuzzaman M, Patwary MI, Rahman MH. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis. Bangladesh Medical Research Council Bulletin. 2000 Apr; 26(1): 1-7en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/519
dc.language.isoengen_US
dc.source.urihttps://www.banglajol.info/index.php/BMRCB/indexen_US
dc.subject.meshAdulten_US
dc.subject.meshAnorexia --chemically induceden_US
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal --therapeutic useen_US
dc.subject.meshAntirheumatic Agents --administration & dosageen_US
dc.subject.meshArthritis, Rheumatoid --drug therapyen_US
dc.subject.meshChi-Square Distributionen_US
dc.subject.meshDrug Combinationsen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHemoglobins --drug effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshLeukocyte Counten_US
dc.subject.meshMaleen_US
dc.subject.meshMethotrexate --administration & dosageen_US
dc.subject.meshNausea --chemically induceden_US
dc.subject.meshNeutrophils --drug effectsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshStatistics, Nonparametricen_US
dc.subject.meshSulfasalazine --administration & dosageen_US
dc.titleEfficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.en_US
dc.typeClinical Trialen_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
dc.typeRandomized Controlled Trialen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Bangladesh Medical Research Council Bulletin